Stenger Family Office LLC Acquires New Holdings in Eli Lilly and Company $LLY

Stenger Family Office LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, Holdings Channel reports. The firm acquired 2,987 shares of the company’s stock, valued at approximately $2,270,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. Clear Street LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $21,008,000. Shepherd Financial Partners LLC raised its position in Eli Lilly and Company by 2.3% in the 2nd quarter. Shepherd Financial Partners LLC now owns 9,729 shares of the company’s stock worth $7,584,000 after purchasing an additional 222 shares during the last quarter. StoneX Group Inc. lifted its stake in shares of Eli Lilly and Company by 34.3% during the second quarter. StoneX Group Inc. now owns 11,028 shares of the company’s stock valued at $8,596,000 after acquiring an additional 2,814 shares during the period. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth about $356,000. Finally, Vance Wealth LLC grew its position in shares of Eli Lilly and Company by 13.8% during the 2nd quarter. Vance Wealth LLC now owns 455 shares of the company’s stock worth $355,000 after buying an additional 55 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on LLY shares. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Wolfe Research boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a research note on Monday, November 10th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,087.32.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,009.26 on Friday. The stock’s 50 day moving average is $918.84 and its 200 day moving average is $809.30. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The firm has a market cap of $954.13 billion, a P/E ratio of 49.38, a P/E/G ratio of 1.13 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.